MX2024000936A - Sal de ulodesina. - Google Patents
Sal de ulodesina.Info
- Publication number
- MX2024000936A MX2024000936A MX2024000936A MX2024000936A MX2024000936A MX 2024000936 A MX2024000936 A MX 2024000936A MX 2024000936 A MX2024000936 A MX 2024000936A MX 2024000936 A MX2024000936 A MX 2024000936A MX 2024000936 A MX2024000936 A MX 2024000936A
- Authority
- MX
- Mexico
- Prior art keywords
- ulodesine
- salt
- 1ylmethyl
- pyrrolo
- pyrrolidin
- Prior art date
Links
- AFNHHLILYQEHKK-BDAKNGLRSA-N 7-[[(3r,4r)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one Chemical class C1[C@H](O)[C@@H](CO)CN1CC1=CNC2=C1NC=NC2=O AFNHHLILYQEHKK-BDAKNGLRSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical group OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 abstract 1
- 229950002816 ulodesine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/12—Glutaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2110403.9A GB202110403D0 (en) | 2021-07-20 | 2021-07-20 | Ulodesine Salt |
| PCT/EP2022/070369 WO2023001893A1 (en) | 2021-07-20 | 2022-07-20 | Ulodesine salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000936A true MX2024000936A (es) | 2024-06-19 |
Family
ID=77443478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000936A MX2024000936A (es) | 2021-07-20 | 2022-07-20 | Sal de ulodesina. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4373579A1 (enExample) |
| JP (1) | JP2024525254A (enExample) |
| KR (1) | KR20240038017A (enExample) |
| CN (1) | CN117897383A (enExample) |
| AU (1) | AU2022314207A1 (enExample) |
| CA (1) | CA3226849A1 (enExample) |
| GB (1) | GB202110403D0 (enExample) |
| MX (1) | MX2024000936A (enExample) |
| WO (1) | WO2023001893A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202218782D0 (en) | 2022-12-13 | 2023-01-25 | Mehrling Thomas | Purine nucleoside phosphorylase inhibitor for metabolic syndrome |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553839B2 (en) | 2002-08-21 | 2009-06-30 | Industrial Research Limited | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| MX2011009928A (es) * | 2009-03-24 | 2012-03-16 | Biocryst Pharm Inc | Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona. |
-
2021
- 2021-07-20 GB GBGB2110403.9A patent/GB202110403D0/en not_active Ceased
-
2022
- 2022-07-20 KR KR1020247005390A patent/KR20240038017A/ko active Pending
- 2022-07-20 CA CA3226849A patent/CA3226849A1/en active Pending
- 2022-07-20 EP EP22754840.1A patent/EP4373579A1/en active Pending
- 2022-07-20 JP JP2024503814A patent/JP2024525254A/ja active Pending
- 2022-07-20 WO PCT/EP2022/070369 patent/WO2023001893A1/en not_active Ceased
- 2022-07-20 MX MX2024000936A patent/MX2024000936A/es unknown
- 2022-07-20 AU AU2022314207A patent/AU2022314207A1/en active Pending
- 2022-07-20 CN CN202280050721.6A patent/CN117897383A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240038017A (ko) | 2024-03-22 |
| GB202110403D0 (en) | 2021-09-01 |
| WO2023001893A4 (en) | 2023-03-30 |
| CA3226849A1 (en) | 2023-01-26 |
| JP2024525254A (ja) | 2024-07-11 |
| CN117897383A (zh) | 2024-04-16 |
| WO2023001893A1 (en) | 2023-01-26 |
| EP4373579A1 (en) | 2024-05-29 |
| AU2022314207A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20247679B (en) | Bicyclic heterocycles as fgfr inhibitors | |
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| PH12012500778A1 (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
| MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| PH12018500944B1 (en) | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND | |
| AU2011288503A8 (en) | 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors | |
| PH12012501749A1 (en) | Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | |
| NZ594057A (en) | Processes for preparing jak inhibitors and related intermediate compounds | |
| MX2009005588A (es) | Polimorfos de sal de succinato de 2-[6-(3-amino-piperidin-1-ilo)-3 -metil,-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-be nzonitrilo y metodos de uso para los mismos. | |
| PH12021552693A1 (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| EA201190205A1 (ru) | ПОЛЕЗНЫЕ ФАРМАЦЕВТИЧЕСКИЕ СОЛИ 7-[(3R,4R)-3-ГИДРОКСИ-4-ГИДРОКСИМЕТИЛПИРРОЛИДИН-1-ИЛМЕТИЛ]-3,5-ДИГИДРОПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНА | |
| WO2005021536A3 (en) | Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors | |
| MX342873B (es) | Derivados de pirazolo-quinazolina sustituidos como inhibidores de cinasa. | |
| MX2011008452A (es) | Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata. | |
| ZA202401459B (en) | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one | |
| IL198270A0 (en) | Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol | |
| NZ602578A (en) | Polymorphic forms st-246 and methods of preparation | |
| CA3246194A1 (en) | PROCESSES AND COMPOSITIONS FOR THE ENZYMATIC PRODUCTION OF PSEUDOURIDIN TRIPHOSPHATE | |
| MY155721A (en) | A process for the preparation of (3ar, 4s, 6r, 6as)-6-amino-2, 2-dimethyltetrahydro-3ah-cyclopenta[d] [1,3] dioxol-4-ol dibenzoyl-l-tartrate and to products of said process | |
| PH12019502462A1 (en) | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors | |
| MX390505B (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2 | |
| NZ719983A (en) | Methods of preparing ophthalmic formulations and uses of same | |
| MX2015000336A (es) | Inhibidores de la enzima fosfodiesterasa 10. | |
| MX386174B (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2 | |
| DE60100855D1 (de) | 1,8-naphthalimid imidazo[4,5,1-de]acridone mit antitumorwirkung |